Berkshire Hathaway Inc. (BRK-A) vs Eli Lilly and Company (LLY)

See how Berkshire Hathaway Inc. and Eli Lilly and Company differ across market data and performance, so you can decide which asset best fits your strategy.

$744,318.4

NYSE

View Full Page

$1,203.4

NYSE

Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.

View Full Page

Key Metrics Comparison

Berkshire Hathaway Inc.BRK-A

Market Cap

$1.07T

Price

$744,318.4

24h Change

+1.04%

24h Volume

$80

Employees

387,800

Shares Outstanding

N/A

Eli Lilly and CompanyLLY

Market Cap

$1.073T

Price

$1,203.4

24h Change

+1.48%

24h Volume

$826.5K

Employees

50,000

Shares Outstanding

944,818,881

Category Performance

Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.

Market Share

Share of combined market cap

BRK-A

49.9%

LLY

50.1%

Volume Share

Share of combined 24h volume

BRK-A

1.0%

LLY

100.0%

24h Performance

Price change over last 24 hours

BRK-A

1.04%

LLY

1.48%

Price Comparison

Berkshire Hathaway Inc.

Eli Lilly and Company